NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-17-168 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research. The institute seeks teams of researchers working at different levels of analysis and employing integrative, novel, and creative experimental approaches to address high-risk, high-impact questions in basic neuroscience research, or in translational research with the primary objectives of: (a) advancing the state of the science in basic brain and behavior research that will uncover and dissect the underlying mechanisms that will ultimately provide the foundation for understanding mental disorders; (b) supporting the integration and translation of basic and clinical neuroscience research on severe mental illnesses; and/or (c) advancing our understanding of the neurobehavioral developmental mechanisms and trajectories of psychopathology that begin in childhood and adolescence. The Conte Centers program is intended to support interdisciplinary basic neuroscience or translational research demonstrating an extraordinary level of synergy, integration, and potential for advancing the state of the field. This program is intended only for projects that could not be achieved using other, more standard grant mechanisms. The Conte Centers program also provides an opportunity to establish interdisciplinary basic neuroscience or translational research experiences for students and post doctorates.
Notice NOT-OD-17-043 from the NIH Guide for Grants and Contracts
Notice NOT-FD-17-002 from the NIH Guide for Grants and Contracts
Notice NOT-MH-17-013 from the NIH Guide for Grants and Contracts
Notice NOT-CA-17-032 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-ES-17-005 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to stimulate multidisciplinary research projects from the scientific community that use a combination of animal/cell models and non-invasive human placenta tissues or biomarkers to investigate how early life exposures affect placental growth, development, and function, and the subsequent health of the offspring.
Notice NOT-AR-17-016 from the NIH Guide for Grants and Contracts
Notice NOT-HS-17-007 from the NIH Guide for Grants and Contracts
Notice NOT-CA-17-031 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-TR-17-001 from the NIH Guide for Grants and Contracts. The NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules [New Therapeutic Uses (NTU)] program is designed to develop partnerships between pharmaceutical companies and the biomedical research community to advance therapeutics development. This innovative program matches researchers with a selection of pharmaceutical industry assets to test ideas for new therapeutic uses with the ultimate goal of identifying promising new treatments for patients. The program was designed to enable efficient 3-way drug repositioning partnerships between academic, government, and pharmaceutical partners.
Funding Opportunity RFA-TR-17-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications that support testing new therapeutic uses for experimental drugs or biologics (Assets) across a broad range of human diseases unique to pediatric populations. This innovative program allows investigators to propose new therapeutic uses for Assets from pharmaceutical company partners. Strong applications will include scientific evidence that modulation of an Assets target will have a positive impact on the disease/condition. An X02 pre-application is the first step in the application process for RFA-TR-17-002 and RFA-TR-17-003. X02 pre-applications will be evaluated by outside experts. Investigators whose X02 pre-applications are judged to be the most meritorious and relevant to NIH program priorities will be notified of the opportunity to submit a UG3/UH3 application under this FOA. The initial UG3 award will support the development of rigorous, pre-clinical efficacy studies and clinical trial planning activities. If UG3 pre-clinical milestones are met, the UH3 award may be made to support clinical trials.
Funding Opportunity RFA-TR-17-002 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications that support testing new therapeutic uses for experimental drugs or biologics (Assets) across a broad range of human diseases. This innovative program allows investigators to propose new therapeutic uses for Assets from pharmaceutical company partners. Strong applications will include scientific evidence that modulation of an Assets target should have a positive impact on the disease/condition. An X02 pre-application is the first step in the application process for RFA-TR-17-002 and RFA-TR-17-003. X02 pre-applications will be evaluated by outside experts. Investigators whose X02 pre-applications are judged to be the most meritorious and relevant to NIH program priorities will be notified of the opportunity to submit a UG3/UH3 application under this FOA. The initial UG3 award will support the development of rigorous, pre-clinical efficacy studies and clinical trial planning activities. If UG3 pre-clinical milestones are met, the UH3 award may be made to support clinical trials.
Notice NOT-HL-17-487 from the NIH Guide for Grants and Contracts
Notice NOT-HD-17-003 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-17-167 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided planning and/or execution therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools. As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies. This FOA supports novel uses of known/standard clinical imaging agents and methods as well as the evaluation of new agents, systems, or methods. The imaging and image-guided intervention (IGI) investigations, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Centers and/or the NCI's National Clinical Trials Network.
Notice NOT-HD-17-002 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-17-166 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages formative research, intervention development, and pilot-testing of interventions. Primary scientific areas of focus include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention or treatment. For the purposes of this FOA, intervention is defined to include behavioral, social, or structural approaches, as well as combination biomedical and behavioral, social, or structural approaches that prevent acquisition and transmission of HIV infection, or improve clinical outcomes for persons who are HIV infected, or both.
Funding Opportunity PA-17-165 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support Administrative Supplements to active NIMH grants to foster research across the NIMH Strategic Objectives that target the reduction and elimination of mental health disparities by race and ethnicity, geography, and socioeconomic status in the United States. This initiative aims to generate research within the scientific scope of the parent grant that identifies mechanisms underlying disparities or differences in mental health status and/or enhances optimal delivery of mental health interventions among diverse groups.
Funding Opportunity PA-17-164 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) announces the availability of administrative supplements to support aging biology research that addresses disparities in health.
Funding Opportunity RFA-DE-18-008 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages hypothesis driven basic, translational and pre-clinical science research to develop novel approaches for prophylactic oral mucosal vaccine that will be synergistic with systemic vaccination for protection against HIV infection.